JP2016510316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510316A5 JP2016510316A5 JP2015549801A JP2015549801A JP2016510316A5 JP 2016510316 A5 JP2016510316 A5 JP 2016510316A5 JP 2015549801 A JP2015549801 A JP 2015549801A JP 2015549801 A JP2015549801 A JP 2015549801A JP 2016510316 A5 JP2016510316 A5 JP 2016510316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- subject
- tables
- mll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745294P | 2012-12-21 | 2012-12-21 | |
| US61/745,294 | 2012-12-21 | ||
| PCT/US2013/077082 WO2014100662A1 (en) | 2012-12-21 | 2013-12-20 | Dot1 l inhibitors for use in the treatment of leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018192426A Division JP2019031525A (ja) | 2012-12-21 | 2018-10-11 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510316A JP2016510316A (ja) | 2016-04-07 |
| JP2016510316A5 true JP2016510316A5 (enExample) | 2017-02-02 |
Family
ID=49956460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549801A Pending JP2016510316A (ja) | 2012-12-21 | 2013-12-20 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
| JP2018192426A Pending JP2019031525A (ja) | 2012-12-21 | 2018-10-11 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018192426A Pending JP2019031525A (ja) | 2012-12-21 | 2018-10-11 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150342979A1 (enExample) |
| EP (1) | EP2934550A1 (enExample) |
| JP (2) | JP2016510316A (enExample) |
| AU (1) | AU2013361076B2 (enExample) |
| CA (1) | CA2894220A1 (enExample) |
| WO (1) | WO2014100662A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014026198A1 (en) | 2012-08-10 | 2014-02-13 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| US9597348B2 (en) | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2016517426A (ja) | 2013-03-15 | 2016-06-16 | エピザイム，インコーポレイティド | 置換プリン化合物の合成方法 |
| EP3169330A4 (en) * | 2014-07-18 | 2018-02-28 | The Regents of the University of Colorado, a body corporate | Dot1l inhibition in patients with mn1-high aml |
| US20170335402A1 (en) * | 2014-08-08 | 2017-11-23 | Baylor College Of Medicine | Dot1l inhibitors and uses thereof |
| WO2016029127A1 (en) * | 2014-08-22 | 2016-02-25 | The Regents Of The University Of Colorado, A Body Corporate | Dot1l inhibitors and uses thereof |
| WO2016044649A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
| EP3200826B1 (en) * | 2014-09-30 | 2021-04-21 | Vecht-lifshitz, Susan Eve | Pharmaceutical compositions for treating ebola virus disease |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| GB201901817D0 (en) | 2019-02-11 | 2019-04-03 | Phoremost Ltd | Methods |
| CN110092804A (zh) * | 2019-03-29 | 2019-08-06 | 广州盈升生物科技有限公司 | 一种含双环基团的嘌呤化合物及其制备方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008041767A1 (en) * | 2006-10-05 | 2008-04-10 | Banyu Pharmaceutical Co., Ltd. | Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| JP2010046057A (ja) * | 2008-07-22 | 2010-03-04 | Akita Univ | 癌細胞の治療感受性増強剤、癌細胞の治療感受性の判定方法、および癌細胞の治療感受性判定キット |
| WO2012075381A1 (en) * | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes |
| US9597348B2 (en) * | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| US10143704B2 (en) * | 2013-11-13 | 2018-12-04 | Epizyme, Inc. | Methods for treating cancer |
-
2013
- 2013-12-20 CA CA2894220A patent/CA2894220A1/en not_active Abandoned
- 2013-12-20 EP EP13821345.9A patent/EP2934550A1/en not_active Withdrawn
- 2013-12-20 WO PCT/US2013/077082 patent/WO2014100662A1/en not_active Ceased
- 2013-12-20 AU AU2013361076A patent/AU2013361076B2/en not_active Ceased
- 2013-12-20 US US14/654,125 patent/US20150342979A1/en not_active Abandoned
- 2013-12-20 JP JP2015549801A patent/JP2016510316A/ja active Pending
-
2018
- 2018-10-11 JP JP2018192426A patent/JP2019031525A/ja active Pending
-
2019
- 2019-09-19 US US16/575,957 patent/US20200113923A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510316A5 (enExample) | ||
| Dai et al. | The potential role of necroptosis in clinical diseases | |
| Showel et al. | Advances in treating acute myeloid leukemia | |
| Tirro et al. | Molecular alterations in thyroid cancer: from bench to clinical practice | |
| Follini et al. | Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia | |
| Badura et al. | Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia | |
| Paoluzzi et al. | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas | |
| Fransecky et al. | Outlook on PI3K/AKT/mTOR inhibition in acute leukemia | |
| Houshmand et al. | Bone marrow microenvironment: The guardian of leukemia stem cells | |
| Wang et al. | Recurrent fusion genes in leukemia: an attractive target for diagnosis and treatment | |
| Etet et al. | Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment | |
| Rizzo et al. | Defining the genomic landscape of head and neck cancers through next‐generation sequencing | |
| Wang et al. | Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation | |
| KR20140040770A (ko) | 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법 | |
| JP2009507918A5 (enExample) | ||
| JP2016522212A5 (enExample) | ||
| Choi et al. | Leukemic stem cells and hematological malignancies | |
| Wang et al. | NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases | |
| Ye et al. | GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways | |
| JP2017503481A5 (enExample) | ||
| An et al. | Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy | |
| Wang et al. | RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: a case report | |
| Chen et al. | Advancements and obstacles of PARP inhibitors in gastric cancer | |
| Zhao et al. | Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions | |
| Stankovic Stojanovic et al. | Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis? |